Ionis earns $40M on Spinraza advance; Five Prime axes Inhibrx deal
⇨ Ionis is picking up another big check from Biogen related to the rollout of Spinraza. The biotech $IONS garnered $40 million on approval of the price in Japan, bringing its total take to $435 million.
⇨ Five Prime Therapeutics is punting its $452 million research pact — which came with a $10 million upfront — with Inhibrx. The biotech axed the deal two days ago, according to an SEC filing.
⇨ Suzhou, China-based CF PharmTech raised $65 million in a D round to support its development and manufacturing work on new inhalation drugs. SDIC Fund Management Corporation led the round.